Our
Clients
: Aug, 2020
: 100
:
Global Antibody Drug Conjugates Market Analysis by Drugs, Mechanism of Action, Application, Technology, End User, Region and segments forecast till 2033
Market Overview
The Antibody Drug Conjugates Market is appreciated to demonstrate a substantial upswing of a CAGR of 12.9% during the forecasted period of 2023 to 2033. The Antibody Drug Conjugates Market is set to be valued at USD 3,198 million in 2023 and is estimated to display a significant improvement of USD 7,475 million by 2033.
Report Scope
Report Attributes | Description |
Market Forecast in 2022 | USD 3,198 million |
Market Forecast in 2033 | USD 7,475 million |
CAGR % 2023-2033 | 12.9% |
Base Year | 2022 |
Historic Data | 2020-2021 |
Forecast Period | 2023-2033 |
Report USP | Product, end-user industry, company share, company heatmap, company Capacity Technology Product capacity, growth factors and more |
Key Companies | AbbVie Inc., ADC Therapeutics, Agensys Inc., Antikor, Astellas Pharma, ADC Therapeutics, Bayer AG, Celldex Therapeutics, Concortis Biotherapeutics, Daiichi Sankyo Company Ltd., Genentech, Gilead Sciences, Inc., GlaxoSmithKline Plc, Heidelberg Pharma, ImmunoGen Inc., Immunomedics Inc., Mersana Therapeutics, Millennium Pharmaceuticals, Oxford Biotherapeutics, Pfizer Inc., Progenics Pharmaceuticals, Roche Holding Ag, Seagen, Inc., Seattle Genetics Inc., Synthon, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., and Others. |
Global Antibody Drug Conjugates Market- Description
Antibody Drug Conjugates are another category of profoundly powerful natural medications manufactured by attaching a small molecule of anticancer drug or another therapeutic drug to an antibody with either permanent or liable linker. The immunizer focuses on a particular antigen just found on target cells. Unlike chemotherapy, Antibody Drug Conjugates (ADCs) are purposefully designed in a way to target and kill tumor cells while sparing the healthy ones. Antibody Drug Conjugate consists of a highly discriminating monoclonal antibody for a cancer related antigen that has limited or no articulation on normal healthy cells. A linker that is steadily available for use, yet delivers the cytotoxic specialist in target cells.
Antibody drug conjugates are comprised of three segments as a target specific antibody antigen, restricted expression on normal cell antigen, a cytotoxic agent designed to kill the primary cancer cell, and a chemical linker to attach cytotoxic agent to the antibody. Antibody drug conjugates have the therapeutic ability and possess both technological and developmental challenges. The antibody conjugates are considered to be ultramodern healing agent. They combine the targeting capacity of monoclonal antibody and aim specific cell killing ability of cytotoxic drugs.
Due to the advancement in technology the antibody conjugates market is achieving success in the global market. Antibody drug market is novel and profoundly powerful natural medication that is receiving attention from both large and small scale pharmaceuticals industries. The potency of the cytotoxic medicine in an antibody drug is 100 to 1000 times more than the cytotoxic drug when it acts alone. Antibody drug conjugates are usually used for in cancer treatment and to help increase cell killing monoclonal antibodies. ADCs consist many advantages such as high tumour sensitivity, restricted systematic exposure, and increased drug tolerability. Rising preclinical research programs, growing number of clinical trials with regards to cancer therapeutics, rising emphasis of pharmaceutical companies for new drug research and discovery and evolution of advanced therapies are some factors that are accelerating the growth.
Antibody Drug Conjugates Market: Key Trends
Unhealthy lifestyle of people twining with rise in tobacco consumption is boosting the market.
Due to unhealthy lifestyle of people across the globe there is steep rise in prevalence of cancer and cancerous diseases. Additionally, surge in tobacco consumption through geographies posing the risk of cancer. As per the report by National Cancer Institute, the number of people existing beyond diagnosis is expected to extend up to 19 million by 2024.
Advancement medical technology is expected to propel the development of the market.
Technological advancement has played a very vital role the in growth of medical sector. Novel discoveries with regards to treatment, cure research, in the medical industry is expected to boost the market growth. Technological advancement has made medical care very much accessible to common public. Rising research activities in the oncology sector and growing association with research institutes is fueling the growth.
COVID-19 impact on the market
Bereavement, isolation, loss of income and fear are triggering mental health conditions or exacerbating existing ones. These are the effects of recent Covid- 19 pandemic that had a calamitous impact on overall supply chain and logistics across globe bringing economic activity near to stand-still. Public finances have been negatively affected. Despite major developments in pharmaceuticals, the spread of infectious diseases is rising across globe due to globalization, increased trade and travel, urbanisation, reviving pathogens and improper use antibiotics etc. The hospital operational activities witnessed a vast impact on account of disruptions in supply chain of ADCs across globe. As per American Cancer Society report in 2021, there was 52% decline in diagnosis of breast cancer cases, while 25% reduction in diagnosis of pancreatic cancer during the period of March to April 2020.
Antibody Drug Conjugates Market: Segmentation Analysis
Antibody Drug Conjugates Market based on Drugs Analysis
Kadcyla
Adcetris
Besponsa
Lumoxiti
Mylotarg
Others
Kadcyla was one of the approved drugs by US and Europe for collateral treatment for early patients of HER2-positive breast cancer. The approval of Kadcyla for early-stage treatment is expected to boost the market.
Antibody Drug Conjugates Market by Mechanism of Action Analysis
HER2 Antibodies
CD30 Antibodies
Others
Antibody Drug Conjugates Market by Application Analysis
Lymphoma
Breast Cancer
Blood Cancer
Skin cancer
Brain Tumor
Ovary Cancer
Brain Cancer
Urothelial & Bladder Cancer
Other Types of Cancer
Among the application segment the blood cancer segment is anticipated to nurture at a CAGR of 19.4% during the anticipated term. This is attributable to rising incidences of cancerous diseases and approval for ADCs.
Antibody Drug Conjugates Market by Technology Analysis
InnunoGen technology
Seattle Genetics technology
Immunomedics technology
Others
Antibody Drug Conjugates Market by End User Analysis
Hospitals
Specialized Cancer Centers
Academic Research Institutes
Biotechnology
Retail Pharmacies
Biopharmaceutical Companies
Others
Antibody Drug Conjugates Market: Geographical ambit
Based on the geographical view, the market occupies regions as North America, Europe, Asia-Pacific, Middle-East and Africa. North America is dominating the market by 57% share revenue and will continue to do so until the forecasted period. This domination attributes to prevalence of high experienced professionals and better healthcare facilities. Additionally, US FDA was first to approve ACD drugs such as Zynlonta, Blenrep, and Trodelv. Following North America, Europe is the second most country to hold a significant share in the global market.
Global Antibody Drug Conjugates Market- Recent Developments
The Antibody Drug conjugates market encompasses several players. There is an aggressive competition. The major players of the market are engaged into intense research and development activities. The key trends of merger and acquisitions in Antibody Drug Conjugates Market are developing. This is the vital strategy adopted by major companies.
Global Antibody Drug Conjugates Market: Company Profiles
AbbVie Inc.
ADC Therapeutics
Agensys Inc.
Antikor
Astellas Pharma
ADC Therapeutics
Bayer AG
Celldex Therapeutics
Concortis Biotherapeutics
Daiichi Sankyo Company Ltd.
Genentech, Gilead Sciences, Inc.
GlaxoSmithKline Plc
Heidelberg Pharma
ImmunoGen Inc.
Immunomedics Inc.
Mersana Therapeutics
Millennium Pharmaceuticals
Oxford Biotherapeutics
Pfizer Inc.
Progenics Pharmaceuticals
Roche Holding Ag
Seagen, Inc.
Seattle Genetics Inc.
Synthon
Takeda Pharmaceutical Company Limited
F. Hoffmann-La Roche Ltd
Others
Global Antibody Drug Conjugates Market: Regional Scope
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Rest of Asia Pacific
South America
Brazil
Argentina
Rest of South America
Middle East and Africa
Saudi Arabia
UAE
Egypt
South Africa
Rest of Middle East and Africa
Why to buy this Report?
Market research: The report provides valuable insights into market trends, growth opportunities, and competitive landscapes. By reading a technology report, businesses and investors can gain a better understanding of the market they are operating in or considering entering, and make more informed decisions based on data and analysis.
Competitive analysis: The report reports provide detailed information on competitors' strengths, weaknesses, and strategies, which can help businesses identify potential threats and opportunities in the market.
Innovation: The report provides insights into emerging technologies and trends, which can help businesses stay up-to-date with the latest developments and make informed decisions about where to invest their resources.
Due diligence: The report can be used by investors and acquirers as part of their due diligence process when considering investing in or acquiring a technology company. These reports can provide valuable information on the company's financials, technology, market position, and other key factors.
Frequently Asked Questions
What is the market size and growth projections?
What is the market size and growth projection for each of the market segments and sub-segments across Countries & Regions?
What are the top performing segments, and countries / regions of each of the markets?
What is the market size and growth rate across key countries / regions?
How big is the global & regional market in terms of revenue and volume?
How far market will grow in forecast period in terms of revenue and volume?
What factors will influence demand and supply trends across each markets during the forecast period?
What are the technology trends shaping various markets?
Which country / region has more opportunities?
What is the COVID-19 impact on the market and how long will it take to recover?
Who are the key competitors of market Players?
What are the market share (%) of Key Players?
What are the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?
What are PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?
1. Global Antibody Drug Conjugates Market Introduction and Market Overview
1.1. Objective of the Market Research Study
1.2. Antibody Drug Conjugates Market Definition & Description
1.3. Research Data Parameters & Reporting Timelines
1.3.1. Historical Data Reporting Years 2020 to 2021
1.3.2. Projected Data Reporting Years 2022 to 2033
1.3.3. Reporting Data Parameters Value (US$ Million)
1.4. Global Antibody Drug Conjugates Market Scope and Market Estimation
1.4.1. Global Antibody Drug Conjugates Overall Market Size (US$ Million), Market CAGR (%), Market Estimates & Forecast (2020 to 2033)
1.4.2. Global Antibody Drug Conjugates Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2020 to 2033
1.5. Antibody Drug Conjugates Market Segmentation
1.5.1. Drugs of Global Antibody Drug Conjugates Market
1.5.2. Technology of Global Antibody Drug Conjugates Market
1.5.3. Mechanism of Action of Global Antibody Drug Conjugates Market
1.5.4. Application of Global Antibody Drug Conjugates Market
1.5.5. End User of Global Antibody Drug Conjugates Market
1.5.6. Key Regions of Global Antibody Drug Conjugates Market
2. Global Antibody Drug Conjugates Market - Executive Summary
2.1. Global Antibody Drug Conjugates Market Summary & Snapshot
2.2. Global Antibody Drug Conjugates Market, By Drugs (US$ Million)
2.3. Global Antibody Drug Conjugates Market, By Technology (US$ Million)
2.4. Global Antibody Drug Conjugates Market, Mechanism of Action (US$ Million)
2.5. Global Antibody Drug Conjugates Market, By Application (US$ Million)
2.6. Global Antibody Drug Conjugates Market, By End User (US$ Million)
2.7. Global Antibody Drug Conjugates Market, By Geography (US$ Million)
2.8. Global Antibody Drug Conjugates Market Outlook & Future Opportunities
3. Antibody Drug Conjugates Market Trends, Outlook, and Factors Analysis
3.1. Global Antibody Drug Conjugates Market Industry Development Trends under COVID-19 Outbreak
3.1.1. Global COVID-19 Status Overview
3.1.2. Influence of COVID-19 Outbreak on Global Antibody Drug Conjugates Market Industry Development
3.1.3. Pre & Post COVID-19 Trends and Scenarios
3.2. Antibody Drug Conjugates Market Dynamics (Growth Impacting Factors & Rationales)
3.2.1. Drivers
3.2.1.1. Raising the number of new product lines and approvals of new techniques
3.2.1.2. Raising the number of numerous cancer types like blood cancer, skin cancer and Breast cancer
3.2.1.3. government-funded research and development activities and advanced medical infrastructure
3.2.1.4. Driver 4
3.2.1.5. Driver 5
3.2.2. Restraints
3.2.2.1. Huge manufacturing cost and maintenance cost
3.2.2.2. Lake of knowledge and advance medical technologies
3.2.3. Opportunities
3.2.3.1. Ongoing oncology research to predict cancer occurrence in the early stages or in the future.
3.2.3.2. Infrastructural advancements in medicine are opening new doors of opportunity.
3.2.3.3. Surgical tool improvement for small surgical tools and easy surgery is a key opportunity
3.2.3.4. Opportunity 4
3.2.3.5. Opportunity 5
3.3. Ecosystem/ Value Chain Analysis
3.4. Porters Five Forces Analysis
3.5. SWOT Analysis
3.6. PEST Analysis
3.7. Average Selling Prices and Pricing Trends Analysis of Antibody Drug Conjugates Market
3.8. Technological Roadmap
3.9. Key Investment Pockets of Antibody Drug Conjugates Market
3.9.1. By Drugs
3.9.2. By Technology
3.9.3. By Mechanism of Action
3.9.4. By Application
3.9.5. By End User
3.9.6. By Regions
4. Global Antibody Drug Conjugates Market: Estimates & Historic Trend Analysis (2020 to 2021)
4.1. Global Antibody Drug Conjugates Market, 2020 2021 (US$ Million)
4.2. Global Antibody Drug Conjugates Market, By Drugs, 2020 to 2021 (US$ Million)
4.3. Global Antibody Drug Conjugates Market, By Technology, 2020 to 2021 (US$ Million)
4.4. Global Antibody Drug Conjugates Market, By Mechanism of Action, 2020 to 2021 (US$ Million)
4.5. Global Antibody Drug Conjugates Market, By Application, 2020 to 2021 (US$ Million)
4.6. Global Antibody Drug Conjugates Market, By End User, 2020 to 2021 (US$ Million)
4.7. Global Antibody Drug Conjugates Market, By Region, 2020 to 2021 (US$ Million)
5. Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by Drugs
5.1. Global Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, by Drugs, 2022 & 2031
5.2. Global Antibody Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts, by Drugs, 2022 to 2033
5.2.1. Adcetris
5.2.2. Kadcyla
5.2.3. Besponsa
5.2.4. Lumoxiti
5.2.5. Mylotarg
5.2.6. Others
6. Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by Technology
6.1. Global Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, by Technology, 2022 & 2031
6.2. Global Antibody Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts, by Technology, 2022 to 2033
6.2.1. ImmunoGen technology
6.2.2. Seattle Genetics technology
6.2.3. Immunomedics technology
6.2.4. Others
7. Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by Mechanism of Action
7.1. Global Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, by Mechanism of Action, 2022 & 2031
7.2. Global Antibody Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts, by Mechanism of Action, 2022 to 2033
7.2.1. CD30 Antibodies
7.2.2. HER2 Antibodies
7.2.3. Other Target Types
8. Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by Application
8.1. Global Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, by Application, 2022 & 2031
8.2. Global Antibody Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts, by Application, 2022 to 2033
8.2.1. Breast Cancer
8.2.2. Lymphoma
8.2.3. Blood Cancer
8.2.4. Ovary Cancer
8.2.5. Skin Cancer
8.2.6. Brain Cancer
8.2.7. Brain Tumor
8.2.8. Urothelial & Bladder Cancer
8.2.9. Other Types of Cancer
9. Global Antibody Drug Conjugates Market Estimates & Forecast Trend Analysis, by End User
9.1. Global Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, by End User, 2022 & 2031
9.2. Global Antibody Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts, by End User, 2022 to 2033
9.2.1. Hospital
9.2.2. Specialized Cancer Centers
9.2.3. Academic Research Institutes
9.2.4. Biotechnology
9.2.5. Retail Pharmacies
9.2.6. Biopharmaceutical Companies
9.2.7. Others
10. Global Antibody Drug Conjugates Market Analysis and Forecast, by Region
10.1. Global Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, by Region, 2022 & 2031
10.2. Global Antibody Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts, by Region, 2022 to 2033
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Middle East and Africa
10.2.5. Latin America
11. North America Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
11.1. North America Antibody Drug Conjugates Market Assessments & Key Findings
11.2. North America Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, 2022 & 2031
11.3. North America Antibody Drug Conjugates Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
11.3.1. By Drugs
11.3.2. By Technology
11.3.3. By Mechanism of Action
11.3.4. By Application
11.3.5. By End User
11.3.6. By Major Country
11.3.6.1. The U.S.
11.3.6.2. Canada
12. Europe Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
12.1. Europe Antibody Drug Conjugates Market Assessments & Key Findings
12.2. Europe Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, 2022 & 2031
12.3. Europe Antibody Drug Conjugates Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
12.3.1. By Drugs
12.3.2. By Technology
12.3.3. By Mechanism of Action
12.3.4. By Application
12.3.5. By End User
12.3.6. By Major Country
12.3.6.1. Germany
12.3.6.2. The U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe (includes all other European countries)
13. Asia Pacific Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
13.1. Asia Pacific Antibody Drug Conjugates Market Assessments & Key Findings
13.2. Asia Pacific Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, 2022 & 2031
13.3. Asia Pacific Antibody Drug Conjugates Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
13.3.1. By Drugs
13.3.2. By Technology
13.3.3. By Mechanism of Action
13.3.4. By Application
13.3.5. By End user
13.3.6. By Major Country
13.3.6.1. China
13.3.6.2. Japan
13.3.6.3. India
13.3.6.4. ASEAN
13.3.6.5. South Korea
13.3.6.6. Rest of Asia Pacific (includes all other Asia Pacific countries)
14. Middle East & Africa Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
14.1. Middle East & Africa Antibody Drug Conjugates Market Assessments & Key Findings
14.2. Middle East & Africa Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, 2022 & 2031
14.3. Middle East & Africa Antibody Drug Conjugates Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
14.3.1. By Drugs
14.3.2. By Technology
14.3.3. By Mechanism of Action
14.3.4. By Application
14.3.5. By End User
14.3.6. By Major Country
14.3.6.1. GCC
14.3.6.2. South Africa
14.3.6.3. Egypt
14.3.6.4. Rest of Middle East & Africa (includes all other Middle East & Africa countries)
15. Latin America Antibody Drug Conjugates Market: Estimates & Forecast Trend Analysis
15.1. Latin America Market Assessments & Key Findings
15.2. Latin America Antibody Drug Conjugates Market Share (%) Estimates and Forecasts, 2022 & 2031
15.3. Latin America Antibody Drug Conjugates Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
15.3.1. By Drugs
15.3.2. By Technology
15.3.3. By Mechanism of Action
15.3.4. By Application
15.3.5. By End User
15.3.6. By Major Country
15.3.6.1. Brazil
15.3.6.2. Mexico
15.3.6.3. Rest of Latin America (includes all other Latin America countries)
16. Competitive Landscape
16.1. Antibody Drug Conjugates Market Revenue Share Analysis (%), by Major Players (2021)
16.2. Antibody Drug Conjugates Market Competition Matrix, by Leading Players
16.3. Antibody Drug Conjugates List of Emerging, Prominent and Leading Players
16.4. Major Mergers & Acquisitions, Partnership, Joint Venture, Expansions, Deals, Recent Developments, etc.
17. Company Profiles
17.1. F. Hoffmann-La Roche Ltd.
17.1.1. Company Overview & Insights
17.1.2. Financial Performance
17.1.3. Product / Service Portfolio
17.1.4. Geographical Footprint & Share
17.1.5. Strategic Initiatives & Key Developments
*Similar details would be provided for all the players mentioned below
17.2. AbbVie Inc.
17.3. ADC Therapeutics
17.4. Agensys Inc.
17.5. Antikor
17.6. Astellas Pharma, ADC Therapeutics
17.7. Bayer AG
17.8. Celldex Therapeutics
17.9. Concortis Biotherapeutics
17.10. Daiichi Sankyo Company Ltd.
17.11. Genentech
17.12. Gilead Sciences, Inc.
17.13. GlaxoSmithKline Plc
17.14. Heidelberg Pharma
17.15. ImmunoGen Inc.
17.16. Immunomedics Inc.
17.17. Mersana Therapeutics
17.18. Millennium Pharmaceuticals
17.19. Oxford Biotherapeutics.
17.20. Pfizer Inc.
17.21. Progenics Pharmaceuticals
17.22. Roche Holding Ag
17.23. Seagen, Inc.
17.24. Seattle Genetics Inc.
17.25. Synthon
17.26. Takeda Pharmaceutical Company Limited
17.27. Others
18. Assumptions and Research Methodology
18.1. Data Mining
18.2. Secondary Research
18.3. Primary Research
18.4. Subject Matter Expert Advice
18.5. Quality Check
18.6. Final Review
18.7. Data Triangulation
18.8. Bottom-Up Approach
18.9. Top Down Approach
18.10. Research Flow
18.11. Key Insights from Industry Experts
18.12. Data Sources
18.13. Assumptions
18.14. Limitations
19. Conclusions and Recommendations
19.1. Key Research Findings and Conclusion
19.2. Key Insights & Recommendations from Analysts